What changed from existing technology?
This study looked at factors that affect how well radium-223 therapy works in men with advanced prostate cancer that has spread to the bones. It found that patients who finished all their treatments and had certain blood test results had better outcomes.
This study identifies specific clinical factors that predict outcomes for radium-223 treatment in bone metastatic castration-resistant prostate cancer, which could help personalize therapy decisions.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
ion-free survival (rPFS), and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases treated with
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This study may help clinicians identify patients who are more likely to benefit from radium-223 therapy based on specific clinical markers, potentially guiding treatment strategies for bone metastatic castration-resistant prostate cancer.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.